SYRE Spyre Therapeutics, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
12:14
Aug 26
Aug 26
News wire reports multiple price target cuts across a broad set of stocks including DKS, INTU.
News wire reports multiple price target cuts across a broad set of stocks including DKS, INTU, and SYRE, alongside new coverage initiations and resumptions from various analysts.
11:48
Aug 26
Aug 26
Premarket movers report shows mixed stock reactions to earnings and guidance.
Premarket movers report shows mixed stock reactions to earnings and guidance, with Nvidia and Mag 7 mostly higher ahead of Wednesday's earnings, while several companies like Intuit, Kohl's, and Zoom fall on weak forecasts and others like Photronics and Semtech rise on beats.
20:08
Aug 25
Aug 25
Author sarcastically dismisses the SYRE indication as a flop and pivots back to an insurance.
Author sarcastically dismisses the SYRE indication as a flop and pivots back to an insurance scam thesis without taking a directional position.
LOW
13:09
Aug 17
Aug 17
Author shares a net conviction chart listing multiple biotech tickers without explicit position.
Author shares a net conviction chart listing multiple biotech tickers without explicit position language, so these are indexed as watch rather than directional calls.
LOW
12:58
Aug 17
Aug 17
Reports largest aggregate Q2 fund holdings
"Reports largest aggregate Q2 2026 holdings across 95 specialist funds based on 13F filings, no directional view."
MED
12:53
Aug 17
Aug 17
Reports widest ownership across specialist funds
"Reports widest Q2 2026 ownership across 95 specialist funds based on 13F filings, no directional view."
MED
12:49
Aug 17
Aug 17
Reports most added positions across funds
"Reports most added positions across specialist funds from Q1 to Q2 2026, no directional view."
MED
12:31
Aug 17
Aug 17
Notes large aggregate Q2 fund holdings
Notes the stock is among the largest aggregate Q2 holdings across 93 funds based on 13F filings.
MED
11:28
Aug 17
Aug 17
A news wire reports a broad list of price target cuts across multiple sectors by various banks.
A news wire reports a broad list of price target cuts across multiple sectors by various banks, alongside several coverage initiations and resumptions with new price targets, all without expressing any personal market view.
11:52
Jul 28
Jul 28
Goldman Sachs upgrades CIB to Buy, KeyBanc upgrades FLY to Overweight.
Goldman Sachs upgrades CIB to Buy, KeyBanc upgrades FLY to Overweight, and multiple other analyst upgrades and downgrades are reported across a wide range of stocks with specific price target changes.
12:51
Jul 24
Jul 24
Author argues SNY already has relevant assets and sees no reason to pursue SYRE or ORKA at high.
Author argues SNY already has relevant assets and sees no reason to pursue SYRE or ORKA at high cost, but does not state a personal position.
LOW
12:36
Jul 24
Jul 24
Author questions the rationale behind SNY's potential acquisition of SYRE given overlapping.
Author questions the rationale behind SNY's potential acquisition of SYRE given overlapping assets, expressing skepticism without taking a directional position.
LOW
15:13
Jun 22
Jun 22
Skeptical about HLE mAb valuations; questions high price tags for SYRE and ORKA.
MED
15:57
Jun 20
Jun 20
Short SYRE — faces more biosimilar competition than peers.
Short SYRE — faces more biosimilar competition than peers, pharmas already developing competing extended half-life IL23s and a4b7 internally, requires massive dilutive capital raises for long combination trials, no credible M&A acquirer identified, yet trades at a multi-billion premium that makes no structural sense.
MED
15:35
Jun 20
Jun 20
The author questions who would buy ORKA or SYRE given ABBV's extended half-life IL-23.
The author questions who would buy ORKA or SYRE given ABBV's extended half-life IL-23, implying competitive risk but without a clear position or forward call.
LOW
13:50
Jun 15
Jun 15
Author notes Spyre's market cap and high share count but does not state a personal position.
Author notes Spyre's market cap and high share count but does not state a personal position or forward call, only a factual observation.
LOW
13:33
Jun 15
Jun 15
SYRE trades at a comparable market cap to a fully post-Phase 3 competitor despite being 6-8.
SYRE trades at a comparable market cap to a fully post-Phase 3 competitor despite being 6-8 years behind in development with undifferentiated me-too pipeline assets — author implies significant overvaluation relative to clinical stage and pipeline quality.
MED
12:54
Jun 15
Jun 15
Short SYRE — Phase 2a open-label data fails to clear blinded clinical remission benchmarks.
Short SYRE — Phase 2a open-label data fails to clear blinded clinical remission benchmarks already set by same-MOA drugs in Phase 3, and the press release omits anti-drug antibody (ADA) disclosure, a known class-killing risk for TL1a inhibitors, suggesting either concealment or a looming data problem.
MED
12:31
Jun 15
Jun 15
Short SYRE — Phase 2a open-label data fails to clear the blinded clinical remission benchmarks.
Short SYRE — Phase 2a open-label data fails to clear the blinded clinical remission benchmarks already set by same-MOA competitors in Phase 3, suggesting the stock is being propped up on scientifically inferior data with no durable catalyst to justify current valuation.
MED
12:13
Jun 10
Jun 10
Author speculates about potential acquisition targets for Sanofi but uses hedged language.
Author speculates about potential acquisition targets for Sanofi but uses hedged language and does not state a personal position or directional view.
LOW
15:10
Jun 04
Jun 04
The author compares market caps of SYRE and ABVX to highlight a perceived valuation disparity.
The author compares market caps of SYRE and ABVX to highlight a perceived valuation disparity but does not state a personal position or forward call.
LOW
13:38
May 19
May 19
Buy SYRE, ORKA, and APGE as the triple combination appears undervalued relative to alternatives.
Buy SYRE, ORKA, and APGE as the triple combination appears undervalued relative to alternatives, with potential upside from oncology inclusion.
HIGH
12:41
May 19
May 19
Avoid SYRE, ORKA, and APGE due to overvaluation vs.
Avoid SYRE, ORKA, and APGE due to overvaluation vs. a private competitor with superior bispecific platform, broader pipeline, and lower trial risk; the author questions the durability of their clinical data and rationale for separate companies.
HIGH
12:07
May 19
May 19
Bearish view on SYRE due to an extended commercialization timeline (2034+).
Bearish view on SYRE due to an extended commercialization timeline (2034+), significant future dilution, and me-too biosimilar targets that make the current $7.5B market cap unsustainable even with 15% annual return assumptions.
HIGH
11:26
May 19
May 19
The author questions the feasibility of lengthy and costly Phase 3 UC maintenance trials.
The author questions the feasibility of lengthy and costly Phase 3 UC maintenance trials for SYRE, implying skepticism about the drug's timeline and competitive edge despite a $7.5B open-label data asset.
MED
16:10
May 07
May 07
The tweet lists four biotech tickers with no directional commentary or forward-looking thesis.
The tweet lists four biotech tickers with no directional commentary or forward-looking thesis, merely sharing a link without expressing a bullish or bearish view.
HIGH
18:11
May 01
May 01
Bearish view on SYRE because its current ~$8.2B valuation is unjustified by only open label.
Bearish view on SYRE because its current ~$8.2B valuation is unjustified by only open label data; even a 33% drop leaves an inflated ~$5.5B cap, implying further downside.
HIGH
18:07
May 01
May 01
Adam May notes ORKA dropped 30% from Monday's high and links to SYRE.
Adam May notes ORKA dropped 30% from Monday's high and links to SYRE, but provides no forward-looking opinion or trade thesis.
HIGH
19:00
Apr 30
Apr 30
Adam May suggests ABVX's potential $15B deal with a novel MOA post-phase 3 offers a better.
Adam May suggests ABVX's potential $15B deal with a novel MOA post-phase 3 offers a better risk-weighted return than SYRE's me-too pipeline, implying SYRE is overvalued at over $8B.
18:38
Apr 30
Apr 30
Bearish view on SYRE as its $8B+ valuation is unjustified compared to ABVX; SYRE’s me-too MOA.
Bearish view on SYRE as its $8B+ valuation is unjustified compared to ABVX; SYRE’s me-too MOA, open-label P2a data, impending generic competition, and multiple rivals do not warrant a premium over ABVX’s breakthrough P3 with zero intra-MoA competition.
HIGH
About SYRE Analyst Coverage
Buzzberg tracks SYRE (Spyre Therapeutics, Inc. Common Stock) across 4 sources. 0 bullish vs 6 bearish calls from 4 analysts. Sentiment: mixed to bearish. 42 total trade ideas tracked. Latest voices: DeItaone, zerohedge, A May MD.